Articles tagged "Calcineurin"

2022 American Transplant Congress
Long-Term Low-Dose Corticosteroid Therapy Can Suppress Calcineurin Inhibitor Induced Nephrotoxicity without Steroid-Related Complication in Living Kidney Transplant Recipient
H. Sasaki, H. Harada, D. Takamoto, Y. Takada, S. Harada, H. Tanaka
Sapporo City General Hospital, Sapporo, Japan
*Purpose: The induction of calcineurin inhibitors (CNI) greatly reduced the rate of allograft rejection, although their chronic use resulted in vascular inflammation in kidney transplant…
2022 American Transplant Congress
Post Transplant Virologic Outcomes in DCD Kidney Transplant Recipients Treated with Thymoglobulin Induction Immunosuppression and Maintenance Belatacept vs Calcineurin Inhibitor Therapy
T. Engebretsen¹, M. Kueht¹, A. Lea², M. Mujtaba³
¹Abdominal Transplant Surgery, University of Texas Medical Branch, Galveston, TX, ²Infectious Disease, University of Texas Medical Branch, Galveston, TX, ³Nephrology, University of Texas Medical Branch, Galveston, TX
*Purpose: Belatacept is an inhibitor of the T-Cell costimulatory pathway that can be used in recipients of Donation after Circulatory Death (DCD) where the intended…
2022 American Transplant Congress
Pediatric Liver Transplant Factors That Influence Tacrolimus Absorption
M. Chandran¹, D. Yoeli¹, A. Sater², F. Karrer¹, M. Adams¹
¹Children's Hospital Colorado, Aurora, CO, ²University of Colorado, Aurora, CO
*Purpose: The aim of this study was to investigate the association between various pediatric recipient characteristics at time of liver transplant and FK506 absorption 6…
2022 American Transplant Congress
Impact of Biliary Reconstruction on Tacrolimus Absorption in Pediatric Liver Transplant
M. Chandran¹, D. Yoeli¹, A. Sater², M. Adams¹, F. Karrer¹
¹Children's Hospital Colorado, Aurora, CO, ²University of Colorado, Aurora, CO
*Purpose: Tacrolimus (FK506) oral bioavailability in pediatric liver transplant recipients (LTR) is poor. Enteral FK506 is primarily absorbed in the small intestine and subject to…
2022 American Transplant Congress
Post-Kidney Transplant Dementia Risk by Modifiable Risk Factors and CNIs Among Older Recipients
Y. Chen¹, J. Ahn¹, N. Chu¹, S. Bae¹, M. A. Schnitzler², G. Hess³, K. Lentine⁴, D. Segev⁵, M. McAdams-DeMarco¹
¹Johns Hopkins School of Medicine, Baltimore, MD, ²Surgery, Saint Louis University, O Fallon, IL, ³Drexel University School of Medicine, Philadelphia, PA, ⁴Saint Louis University, St. Louis, MO, ⁵Johns Hopkins University, Baltimore, MD
*Purpose: Up to 17% of older recipients develop dementia after kidney transplant (KT). While there are known modifiable risk factors for dementia among community-dwelling older…
2022 American Transplant Congress
Evaluation of Different Initial Tacrolimus Dosing Regimens in Pediatric Post-Liver Transplantation
A. F. Alghanem¹, A. Alsmari¹, H. Joharji²
¹Pharmaceutical Care, King Abdulaziz Medical City, Riyadh, Saudi Arabia, ²Pharmaceutical Care, King Faisal Specialized Hospital and Research Center, Riyadh, Saudi Arabia
*Purpose: Tacrolimus is an immunosuppressant used in post-liver transplantation, has wide pharmacokinetic variability, particularly in pediatric patients. Therefore, this study aimed to evaluate different weight-based…
2021 American Transplant Congress
Relationship Between Tacrolimus Blood Levels and Covid-19 Pandemic in Kidney Transplant Recipients
T. Inoue¹, K. Unagami,², A. Ishiwatari³, T. Kanzawa³, T. Shimizu³, K. Omoto³, M. Inui³, T. Suzuki¹, H. Ishida⁴, K. Tanabe³
¹Department of Nephrology, Kameda Medical Center, Chiba Kamogawa, Japan, ²Department of Organ Transplant Medicine, Tokyo Women’s Medical University, Tokyo, Japan, ³Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Department of Organ transplant medicine, Tokyo Women’s Medical University, Tokyo, Japan
*Purpose: The novel coronavirus 2019 infection (COVID-19) caused a pandemic, prompting Tokyo, Japan, to restrict on the free movement of people in March 2020. Kidney…
2021 American Transplant Congress
A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression
E. Huang, A. Vo, A. Peng, R. Najjar, S. Sethi, S. Jordan
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…
2021 American Transplant Congress
Higher Calcineurin Inhibitor Levels Associate with Graft Outcomes in Kidney Recipients with De Novo Donor-specific Antibodies of Either Hla Class I or II
M. Béland, S. De Serres
Nephrology, CHU de Québec- Université Laval, Québec, QC, Canada
*Purpose: The development of de novo anti-HLA donor specific antibodies (dnDSA) is associated with poorer outcomes in kidney transplant recipients. We and other previously reported…
2021 American Transplant Congress
Evaluation of the Conversion from Tacrolimus to Sirolimus in Liver Transplant Recipients
H. Bakhtiari¹, S. Todd², H. Snyder², D. Lo², M. Flynn²
¹Mercer University College of Pharmacy, Atlanta, GA, ²Emory University Hospital, Atlanta, GA
*Purpose: The purpose of this study was to compare outcomes in liver transplant patients maintained on standard calcineurin inhibitor (CNI) therapy with tacrolimus versus those…